We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...
StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...
7h
The growing existence of viral infections is driving the viral sensitizers market.New York, USA, Dec. 03, 2024 (GLOBE ...
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on November 25 and set a price target of ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
On Tuesday, Canaccord Genuity maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a price target of $384.00. The firm's analyst commented on recent developments in the ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
On Monday, BMO Capital maintained its optimistic outlook on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), reiterating an Outperform rating with a $300.00 price target. The firm's confidence is ...
CAMBRIDGE, MA—Kevin Joseph Fitzgerald, the Chief Scientific Officer and Executive Vice President, Head of Research at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently sold a significant portion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback